Problem

Protein-based drugs can deliver powerful therapeutic effects, but their development and production are expensive and difficult to scale. Invitris cites a mismatch in which protein-based drugs represent only 2% of treatments but generate 40% of drug revenue, while conventional production relies on living cells such as bacteria; handling those cells is error-prone, scales poorly, and requires a new process for each drug. This makes it costly and slow to explore many protein designs.

Invitris’s killer use case is antimicrobial-resistance treatment, especially synthetic bacteriophages and related proteins. Its phages are intended to attack disease-causing bacteria, including antibiotic-resistant pathogens, offering a potential alternative as multidrug-resistant infections become a major health-economic threat. The company has also identified endolysins and other antimicrobial proteins as initial focus areas.

Product / Service

Invitris’s core product is Phactory, a patent-pending, universal cell-free protein-synthesis platform that converts DNA into synthetic proteins in a single step. Rather than growing and engineering living production cells for every new molecule, Phactory recreates the relevant molecular machinery in vitro. The company describes both prokaryotic and mammalian cell-free systems, supporting microbial proteins as well as complex proteins requiring features such as glycosylation and disulfide bonds.

The delivery model is partnership-led: Invitris works with biopharmaceutical companies and other life-science organizations to bring products into development pipelines. Its platform combines automation, computational protein design, high-throughput screening, microfluidics, and production that can scale from picoliter reactions to liter-scale volumes. The intended benefit is faster, more flexible protein discovery and manufacturing; company materials claim more than 10,000-fold greater design efficiency and roughly 100-fold lower material costs than conventional approaches.

Market

Invitris competes at the intersection of cell-free protein synthesis, synthetic biology, protein engineering, biopharmaceutical discovery, and antimicrobial or phage therapeutics. Cell-free systems are attractive because they decouple cell growth from protein synthesis and can be integrated with automated liquid handling and microfluidics for rapid, high-throughput screening. Nuclera is the clearest named adjacent competitor in the evidence: it also combines cell-free protein synthesis with digital microfluidics and data analytics to identify and produce proteins in days. Invitris is differentiated by its emphasis on a universal platform, therapeutic protein development, and phage production, while other cell-free expression-kit providers represent additional category competition.

Invitris appears to be an early-stage, pre-commercial-scale company rather than one with publicly demonstrated revenue. It was founded in 2022, entered Y Combinator’s Winter 2023 batch, and was listed with six employees in Munich. It received €250,000 in 2023 INCATE funding to complete its spinout and scale antimicrobial-protein production, followed by a multi-million-euro EIC Accelerator grant and equity investment announced in March 2025 to scale Phactory, advance personalized protein therapies, and move toward clinical translation. The sources do not disclose revenue, named commercial customers, or approved clinical products; the visible traction is therefore financing, technology validation, laboratory development, and active pursuit of biopharmaceutical partnerships rather than proven commercial sales.